Published by mark itwired
Posted on September 6, 2021
9 min readLast updated: February 13, 2026
Add as preferred source on Google
Genital herpes is a common sexually transmitted disease. With the increase in population of various regions, there is also an increase in the rate of health issues around the world. As the rate of diseases grow, the treatment markets are also expected to grow substantially.
With respect to sexually transmitted disease like genital herpes, its treatment market includes different drug types like Acyclovir, Valacyclovir and Famciclovir. The indication of genital herpes include HSV-1 and HSV-2.
According to the market projections given in the report, global genital herpes treatment market is expected to surge and reach a market size of over US$ 2881.8 Mn by the end of 2031. The market is expected to register a CAGR of 4.5% of during the forecast period of 2021-2031.
The market growth is primarily driven by the increase government spending on healthcare industry. Various countries are focused on prevention of infectious diseases which in turn, has a positive impact over the herpes drugs market leading to its high demand from local governments and third-party payers.
The global genital herpes treatment market may witness new opportunities in the market. Globally, the increasing disease burden of herpes continuously provides an opportunity for the diagnostic and treatment market.
According to WHO, in 2016 around 67% of the world population (3.7 Bn) under the age of 50 were suffering from HSV-1 infection. This represents substantial growth of the global HSV disease treatment market over the forecast period. Similarly around 13% of the world population (491 Mn) under the age of 50 is living with HSV-2 infection as of 2016.
Get Report Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1390
The companies are also trying to introduce cost effective treatment methods. New vaccines provide complete protection against a variety of strains of HSV1 and HSV2. Companies are increasing research and development activities for the treatment and prevention of genital herpes diseases. Most of the companies are focusing on approval and launch of generic drugs in the undeveloped countries to provide low cost drugs for the treatment of genital herpes.
MEA is expected to come up as the most lucrative region in the industry. With the rise in sexually transmitted diseases in the region, the demand for genital herpes treatment is also expected to rise.
Regional analysis shows that MEA will witness a robust CAGR of 5.2% during the forecast period in the global genital herpes treatment market. Based on the route of administration oral is the main segment, with the highest growth rate and highest market share in the global genital herpes treatment market.
Amongst various distribution channels, retail pharmacies hold the highest market size, but the segment lags behind in terms of growth rate. With the growth of online marketing and e-commerce, online pharmacies is the fastest growing segment which is expected to register a growth rate of 5.4% during the forecast period.
Some of the leading companies mentioned in the research report are Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Sun Pharmaceuticals Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc., Dr. Reddy’s Laboratories, ltd., Novartis AG, Valeant Pharmaceuticals International Inc., etc.
Speak To Analyst For Queries about Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-1390
Driven by increasing prevalence of genital herpes in younger population across the globe, the genital herpes treatment market is forecast to grow at 4.76% from 2021, reaching the valuation of US$ 1947.2 Mn in 2021.
Between 2016 and 2020, the genital herpes treatment market grew at a 4.0% CAGR.
The global genital herpes treatment sale is forecast to exceed the valuation of US$ 2881.8 Mn by the end of 2031.
Leading countries driving the production of the genital herpes treatment are U.S., China, and India.
Demand registered in North America will continue rising, backed increasing sales in the U.S. and Canada, the North America will engulf around 34.2% of global market share by 2031.
Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd and Abbott Laboratories are the top five companies operating in the market.
Top five market players account for around 54.5% of the global genital herpes treatment market share.
Genital herpes treatment sales will increase at 3.4% CAGR in Europe, backed by rising demand in the U.K., Germany, and other countries.
Leading countries driving demand in the genital herpes treatment market are U.S., China, India Germany, and U.K.
The post Global Genital Herpes Treatment Market Future Outlook, Industry Analysis, Growth and Forecast to 2031 first appeared on Market Research Blog.
Genital herpes is a common sexually transmitted disease. With the increase in population of various regions, there is also an increase in the rate of health issues around the world. As the rate of diseases grow, the treatment markets are also expected to grow substantially.
With respect to sexually transmitted disease like genital herpes, its treatment market includes different drug types like Acyclovir, Valacyclovir and Famciclovir. The indication of genital herpes include HSV-1 and HSV-2.
According to the market projections given in the report, global genital herpes treatment market is expected to surge and reach a market size of over US$ 2881.8 Mn by the end of 2031. The market is expected to register a CAGR of 4.5% of during the forecast period of 2021-2031.
The market growth is primarily driven by the increase government spending on healthcare industry. Various countries are focused on prevention of infectious diseases which in turn, has a positive impact over the herpes drugs market leading to its high demand from local governments and third-party payers.
The global genital herpes treatment market may witness new opportunities in the market. Globally, the increasing disease burden of herpes continuously provides an opportunity for the diagnostic and treatment market.
According to WHO, in 2016 around 67% of the world population (3.7 Bn) under the age of 50 were suffering from HSV-1 infection. This represents substantial growth of the global HSV disease treatment market over the forecast period. Similarly around 13% of the world population (491 Mn) under the age of 50 is living with HSV-2 infection as of 2016.
Get Report Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1390
The companies are also trying to introduce cost effective treatment methods. New vaccines provide complete protection against a variety of strains of HSV1 and HSV2. Companies are increasing research and development activities for the treatment and prevention of genital herpes diseases. Most of the companies are focusing on approval and launch of generic drugs in the undeveloped countries to provide low cost drugs for the treatment of genital herpes.
MEA is expected to come up as the most lucrative region in the industry. With the rise in sexually transmitted diseases in the region, the demand for genital herpes treatment is also expected to rise.
Regional analysis shows that MEA will witness a robust CAGR of 5.2% during the forecast period in the global genital herpes treatment market. Based on the route of administration oral is the main segment, with the highest growth rate and highest market share in the global genital herpes treatment market.
Amongst various distribution channels, retail pharmacies hold the highest market size, but the segment lags behind in terms of growth rate. With the growth of online marketing and e-commerce, online pharmacies is the fastest growing segment which is expected to register a growth rate of 5.4% during the forecast period.
Some of the leading companies mentioned in the research report are Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Sun Pharmaceuticals Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc., Dr. Reddy’s Laboratories, ltd., Novartis AG, Valeant Pharmaceuticals International Inc., etc.
Speak To Analyst For Queries about Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-1390
Driven by increasing prevalence of genital herpes in younger population across the globe, the genital herpes treatment market is forecast to grow at 4.76% from 2021, reaching the valuation of US$ 1947.2 Mn in 2021.
Between 2016 and 2020, the genital herpes treatment market grew at a 4.0% CAGR.
The global genital herpes treatment sale is forecast to exceed the valuation of US$ 2881.8 Mn by the end of 2031.
Leading countries driving the production of the genital herpes treatment are U.S., China, and India.
Demand registered in North America will continue rising, backed increasing sales in the U.S. and Canada, the North America will engulf around 34.2% of global market share by 2031.
Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd and Abbott Laboratories are the top five companies operating in the market.
Top five market players account for around 54.5% of the global genital herpes treatment market share.
Genital herpes treatment sales will increase at 3.4% CAGR in Europe, backed by rising demand in the U.K., Germany, and other countries.
Leading countries driving demand in the genital herpes treatment market are U.S., China, India Germany, and U.K.
The post Global Genital Herpes Treatment Market Future Outlook, Industry Analysis, Growth and Forecast to 2031 first appeared on Market Research Blog.
Genital herpes is a common sexually transmitted infection caused by the herpes simplex virus (HSV), primarily HSV-1 and HSV-2, leading to sores and blisters in the genital area.
Acyclovir is an antiviral medication used to treat infections caused by certain types of viruses, including herpes simplex virus, helping to reduce the severity and duration of outbreaks.
CAGR stands for Compound Annual Growth Rate, which measures the mean annual growth rate of an investment over a specified time period, assuming the investment grows at a steady rate.
Generic drugs are medications that are equivalent to brand-name drugs in dosage, strength, route of administration, quality, and performance but are sold under their chemical name without branding.
HSV-1, or herpes simplex virus type 1, is a strain of the herpes virus that typically causes oral herpes but can also lead to genital herpes through oral-genital contact.
Explore more articles in the Research Reports category
